Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel
NASDAQ:ENGN

enGene Q2 2026 Earnings Report

enGene logo
$1.76 +0.14 (+8.33%)
As of 11:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

enGene EPS Results

Actual EPS
$0.43
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.91
One Year Ago EPS
$0.51

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

enGene Announcement Details

Quarter
Q2 2026
Date
6/15/2026
Time
Before Market Opens
Conference Call Date
Monday, June 15, 2026
Conference Call Time
9:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

enGene's Q2 2026 Press ReleasePress Release
(8-K)
enGene's Q2 2026 Quarterly reportQuarterly report
(10-Q)

enGene Earnings Headlines

Should You Use Thicker Oil In A High-Mileage Engine?
June 14 at 2:19 PM  |  msn.comhttps://www.msn.com/en-us/money/general/should-you-use-thicker-oil-in-a-high-mileage-engine/ar-AA25ByV1
7 Engines From Major Automakers Raising Red Flags In 2026
June 14 at 2:19 PM  |  msn.comhttps://www.msn.com/en-us/autos/general/7-engines-from-major-automakers-raising-red-flags-in-2026/ar-AA25Ctpk
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.tc pixel
June 15 at 1:00 AM  |  Porter & Company (Ad)
World’s first large-scale 100% hydrogen engine feeds power into electricity grid
June 14 at 2:19 PM  |  msn.comhttps://www.msn.com/en-us/money/other/world-s-first-large-scale-100-hydrogen-engine-feeds-power-into-electricity-grid/ar-AA25C8Ka
5 trucks known for the most reliable engines
June 14 at 9:18 AM  |  msn.comhttps://www.msn.com/en-us/autos/trucks/5-trucks-known-for-the-most-reliable-engines/ar-AA22lT08
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
June 11, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/engn-investors-have-opportunity-to-join-engene-therapeutics-inc-fraud-investigation-with-the-schall-law-firm-302797714.html
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN) is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

View enGene Profile
Earnings Tools